• Featured Product
  • KD/KO Validated

IL-32 Polyclonal antibody

IL-32 Polyclonal Antibody for IHC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human and More (1)

Applications

WB, IF, IHC, ELISA

Conjugate

Unconjugated

Cat no : 11079-1-AP

Synonyms

IL 32, IL 32alpha, IL 32beta, IL 32delta, IL 32gamma, IL32, IL-32, interleukin 32, Natural killer cells protein 4, NK4, TAIF, TAIFa, TAIFb, TAIFc, TAIFd



Tested Applications

Positive IHC detected inhuman lung cancer tissue, human colon cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Immunohistochemistry (IHC)IHC : 1:200-1:800
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

11079-1-AP targets IL-32 in WB, IF, IHC, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman, mouse
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen IL-32 fusion protein Ag1484
Full Name interleukin 32
Calculated Molecular Weight 27 kDa
GenBank Accession NumberBC009401
Gene Symbol IL32
Gene ID (NCBI) 9235
RRIDAB_2877745
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Interleukin 32 (IL32) is a member of the cytokine family. IL32 contains a tyrosine sulfation site, 3 potential N-myristoylation sites, multiple putative phosphorylation sites, and an RGD cell-attachment sequence. IL32 is a predominantly intracellular proinflammatory cytokine produced by epithelial cells, monocytes, T-lymphocytes and natural killer cells, and is involved in inflammation and cancer development. IL32 is able to induce the release a variety of pro-inflammatory cytokines such as IL8, tumor necrosis factor-α (TNFα) and IL6. Expression of this protein is increased after the activation of T-cells by mitogens or the activation of NK cells by IL-2.

Protocols

Product Specific Protocols
IHC protocol for IL-32 antibody 11079-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

J Cell Mol Med

MicroRNA-29b-3p suppresses oral squamous cell carcinoma cell migration and invasion via IL32/AKT signalling pathway.

Authors - Jianya He
humanIHC

J Hepatocell Carcinoma

Identification and Validation of Novel Biomarkers for Hepatocellular Carcinoma, Liver Fibrosis/Cirrhosis and Chronic Hepatitis B via Transcriptome Sequencing Technology.

Authors - Dandan Zhao
human,mouseIHC,IF

Front Pharmacol

Targeting TIGIT Inhibits Bladder Cancer Metastasis Through Suppressing IL-32.

Authors - Kang Wu
humanWB,IHC

Oncol Lett

Interleukin-32 regulates downstream molecules and promotes the invasion of pancreatic cancer cells.

Authors - Kohji Takagi
  • KD Validated
humanWB,IF

Oncol Lett

Establishment of highly invasive pancreatic cancer cell lines and the expression of IL-32.

Authors - Kohji Takagi
humanWB

Biomed Res Int

IL-32 Promotes the Radiosensitivity of Esophageal Squamous Cell Carcinoma Cell through STAT3 Pathway.

Authors - Zhiyu Ma